CLIN CANCER RES：新辅助多西他赛联合去势治疗对高风险前列腺癌基因组学和转录组学的影响

2017-11-18 MedSci MedSci原创

多西他赛联合去势治疗已成为转移性前列腺癌的标准治疗方式。近期进行的临床试验CALGB 90203主要的目的观察这一治疗方式在疾病早期的临床效果。在临床试验中获得的标本为探索多西他赛联合去势治疗的分子反应及可能的分子标志提供了机会。CLIN CANCER RES近期发表了一篇文章，研究了这一问题。

多西他赛联合去势治疗已成为转移性前列腺癌的标准治疗方式。近期进行的临床试验CALGB 90203主要的目的观察这一治疗方式在疾病早期的临床效果。在临床试验中获得的标本为探索多西他赛联合去势治疗的分子反应及可能的分子标志提供了机会。CLIN CANCER RES近期发表了一篇文章，研究了这一问题。

作者评估了CALGB 90203临床试验中纳入的52例患者的临床数据、穿刺活检标本和根治性切除后标本。通过病理、DNA测序和表达分析研究前列腺癌中与侵袭和耐药相关通路的变化。研究表明，最常见的改变包括TMPRSS2-ERG融合（n=32），TP53突变或缺失（n=11），PTEN缺失（n=6），FOXA1（n=6）和SPOP（n=4）突变，治疗后的标本中并未显着增加。作者并未观察到AR扩增或突变。治疗后的肿瘤AR信号抑制情况不同，AR和AR-V7表达以及一些神经内分泌基因表达上调。

文章最后认为，该研究数据表明对新辅助治疗后前列腺癌进行靶向基因和转录测序是可行的。治疗后发现的治疗反应异质性和分子异常为寻找可能的耐药标志提供了新的思路。

原始出处：

Himisha Beltran,Alexander W.Wyatt,et al.Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy.CLIN CANCER RES.November 2017 doi:10.1158/1078-0432.CCR-17-1034

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (7)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1862042, encodeId=a6fa18620424a, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Fri Aug 31 03:32:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747282, encodeId=cb8f1e47282bb, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed Jan 24 03:32:00 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678539, encodeId=956316e8539de, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Mon Oct 15 17:32:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632061, encodeId=38951632061c0, content=<a href='/topic/show?id=003b3e23745' target=_blank style='color:#2F92EE;'>#去势治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37237, encryptionId=003b3e23745, topicName=去势治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02f721846554, createdName=zhaozuguo, createdTime=Wed May 23 14:32:00 CST 2018, time=2018-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373919, encodeId=629913e391991, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Mon Nov 20 00:32:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420171, encodeId=fc6714201e124, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Mon Nov 20 00:32:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469698, encodeId=7a2714696980c, content=<a href='/topic/show?id=09224182601' target=_blank style='color:#2F92EE;'>#基因组学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41826, encryptionId=09224182601, topicName=基因组学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0257060332, createdName=gwc385, createdTime=Mon Nov 20 00:32:00 CST 2017, time=2017-11-20, status=1, ipAttribution=)]
2018-08-31 zlawrance

#高风险#

70 0
[GetPortalCommentsPageByObjectIdResponse(id=1862042, encodeId=a6fa18620424a, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Fri Aug 31 03:32:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747282, encodeId=cb8f1e47282bb, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed Jan 24 03:32:00 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678539, encodeId=956316e8539de, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Mon Oct 15 17:32:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632061, encodeId=38951632061c0, content=<a href='/topic/show?id=003b3e23745' target=_blank style='color:#2F92EE;'>#去势治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37237, encryptionId=003b3e23745, topicName=去势治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02f721846554, createdName=zhaozuguo, createdTime=Wed May 23 14:32:00 CST 2018, time=2018-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373919, encodeId=629913e391991, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Mon Nov 20 00:32:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420171, encodeId=fc6714201e124, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Mon Nov 20 00:32:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469698, encodeId=7a2714696980c, content=<a href='/topic/show?id=09224182601' target=_blank style='color:#2F92EE;'>#基因组学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41826, encryptionId=09224182601, topicName=基因组学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0257060332, createdName=gwc385, createdTime=Mon Nov 20 00:32:00 CST 2017, time=2017-11-20, status=1, ipAttribution=)]
2018-01-24 mjldent

#转录#

68 0
[GetPortalCommentsPageByObjectIdResponse(id=1862042, encodeId=a6fa18620424a, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Fri Aug 31 03:32:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747282, encodeId=cb8f1e47282bb, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed Jan 24 03:32:00 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678539, encodeId=956316e8539de, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Mon Oct 15 17:32:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632061, encodeId=38951632061c0, content=<a href='/topic/show?id=003b3e23745' target=_blank style='color:#2F92EE;'>#去势治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37237, encryptionId=003b3e23745, topicName=去势治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02f721846554, createdName=zhaozuguo, createdTime=Wed May 23 14:32:00 CST 2018, time=2018-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373919, encodeId=629913e391991, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Mon Nov 20 00:32:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420171, encodeId=fc6714201e124, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Mon Nov 20 00:32:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469698, encodeId=7a2714696980c, content=<a href='/topic/show?id=09224182601' target=_blank style='color:#2F92EE;'>#基因组学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41826, encryptionId=09224182601, topicName=基因组学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0257060332, createdName=gwc385, createdTime=Mon Nov 20 00:32:00 CST 2017, time=2017-11-20, status=1, ipAttribution=)]
2018-10-15 charl1234576

#新辅助#

72 0
[GetPortalCommentsPageByObjectIdResponse(id=1862042, encodeId=a6fa18620424a, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Fri Aug 31 03:32:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747282, encodeId=cb8f1e47282bb, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed Jan 24 03:32:00 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678539, encodeId=956316e8539de, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Mon Oct 15 17:32:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632061, encodeId=38951632061c0, content=<a href='/topic/show?id=003b3e23745' target=_blank style='color:#2F92EE;'>#去势治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37237, encryptionId=003b3e23745, topicName=去势治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02f721846554, createdName=zhaozuguo, createdTime=Wed May 23 14:32:00 CST 2018, time=2018-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373919, encodeId=629913e391991, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Mon Nov 20 00:32:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420171, encodeId=fc6714201e124, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Mon Nov 20 00:32:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469698, encodeId=7a2714696980c, content=<a href='/topic/show?id=09224182601' target=_blank style='color:#2F92EE;'>#基因组学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41826, encryptionId=09224182601, topicName=基因组学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0257060332, createdName=gwc385, createdTime=Mon Nov 20 00:32:00 CST 2017, time=2017-11-20, status=1, ipAttribution=)]
2018-05-23 zhaozuguo

#去势治疗#

79 0
[GetPortalCommentsPageByObjectIdResponse(id=1862042, encodeId=a6fa18620424a, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Fri Aug 31 03:32:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747282, encodeId=cb8f1e47282bb, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed Jan 24 03:32:00 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678539, encodeId=956316e8539de, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Mon Oct 15 17:32:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632061, encodeId=38951632061c0, content=<a href='/topic/show?id=003b3e23745' target=_blank style='color:#2F92EE;'>#去势治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37237, encryptionId=003b3e23745, topicName=去势治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02f721846554, createdName=zhaozuguo, createdTime=Wed May 23 14:32:00 CST 2018, time=2018-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373919, encodeId=629913e391991, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Mon Nov 20 00:32:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420171, encodeId=fc6714201e124, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Mon Nov 20 00:32:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469698, encodeId=7a2714696980c, content=<a href='/topic/show?id=09224182601' target=_blank style='color:#2F92EE;'>#基因组学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41826, encryptionId=09224182601, topicName=基因组学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0257060332, createdName=gwc385, createdTime=Mon Nov 20 00:32:00 CST 2017, time=2017-11-20, status=1, ipAttribution=)]
2017-11-20 zhucaizhong7766

#癌基因#

91 0
[GetPortalCommentsPageByObjectIdResponse(id=1862042, encodeId=a6fa18620424a, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Fri Aug 31 03:32:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747282, encodeId=cb8f1e47282bb, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed Jan 24 03:32:00 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678539, encodeId=956316e8539de, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Mon Oct 15 17:32:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632061, encodeId=38951632061c0, content=<a href='/topic/show?id=003b3e23745' target=_blank style='color:#2F92EE;'>#去势治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37237, encryptionId=003b3e23745, topicName=去势治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02f721846554, createdName=zhaozuguo, createdTime=Wed May 23 14:32:00 CST 2018, time=2018-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373919, encodeId=629913e391991, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Mon Nov 20 00:32:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420171, encodeId=fc6714201e124, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Mon Nov 20 00:32:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469698, encodeId=7a2714696980c, content=<a href='/topic/show?id=09224182601' target=_blank style='color:#2F92EE;'>#基因组学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41826, encryptionId=09224182601, topicName=基因组学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0257060332, createdName=gwc385, createdTime=Mon Nov 20 00:32:00 CST 2017, time=2017-11-20, status=1, ipAttribution=)]
2017-11-20 marlenexl

#转录组#

71 0
[GetPortalCommentsPageByObjectIdResponse(id=1862042, encodeId=a6fa18620424a, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Fri Aug 31 03:32:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747282, encodeId=cb8f1e47282bb, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed Jan 24 03:32:00 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678539, encodeId=956316e8539de, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Mon Oct 15 17:32:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632061, encodeId=38951632061c0, content=<a href='/topic/show?id=003b3e23745' target=_blank style='color:#2F92EE;'>#去势治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37237, encryptionId=003b3e23745, topicName=去势治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02f721846554, createdName=zhaozuguo, createdTime=Wed May 23 14:32:00 CST 2018, time=2018-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373919, encodeId=629913e391991, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Mon Nov 20 00:32:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420171, encodeId=fc6714201e124, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Mon Nov 20 00:32:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469698, encodeId=7a2714696980c, content=<a href='/topic/show?id=09224182601' target=_blank style='color:#2F92EE;'>#基因组学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41826, encryptionId=09224182601, topicName=基因组学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0257060332, createdName=gwc385, createdTime=Mon Nov 20 00:32:00 CST 2017, time=2017-11-20, status=1, ipAttribution=)]
2017-11-20 gwc385

#基因组学#

84 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科

CLIN CANCER RES：新辅助多西他赛联合去势治疗对高风险前列腺癌基因组学和转录组学的影响

相关资讯

科室

工具

服务